127 related articles for article (PubMed ID: 10945391)
1. Intestinal elimination of hydroxyethyl starch?
Lenz K; Schimetta W; Pölz W; Kröll W; Gruy-Kapral C; Magometschnigg D
Intensive Care Med; 2000 Jun; 26(6):733-9. PubMed ID: 10945391
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers.
Waitzinger J; Bepperling F; Pabst G; Opitz J
Drugs R D; 2003; 4(3):149-57. PubMed ID: 12757400
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6 : 1 and hydroxyethyl starch 130/0.4/9 : 1.
Lehmann G; Marx G; Förster H
Drugs R D; 2007; 8(4):229-40. PubMed ID: 17596109
[TBL] [Abstract][Full Text] [Related]
5. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.
Bellmann R; Feistritzer C; Wiedermann CJ
Clin Pharmacokinet; 2012 Apr; 51(4):225-36. PubMed ID: 22420578
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of acetyl starch as a plasma volume expander in patients undergoing elective surgery.
Behne M; Thomas H; Bremerich DH; Lischke V; Asskali F; Förster H
Anesth Analg; 1998 Apr; 86(4):856-60. PubMed ID: 9539615
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of 6 % hydroxyethyl starch 130/0.4 in healthy male volunteers of Japanese ethnicity after single infusion of 500 ml solution.
Yamakage M; Bepperling F; Wargenau M; Miyao H
J Anesth; 2012 Dec; 26(6):851-7. PubMed ID: 22729229
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).
Degrémont AC; Ismaïl M; Arthaud M; Oulare B; Mundler O; Paris M; Baron JF
Intensive Care Med; 1995 Jul; 21(7):577-83. PubMed ID: 7593900
[TBL] [Abstract][Full Text] [Related]
9. [The accumulation of different substituted hydroxyethyl starches (HES) following repeated infusions in healthy volunteers].
Asskali F; Förster H
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Sep; 34(9):537-41. PubMed ID: 10542895
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and tolerability of acetyl starch as a new plasma volume expander in patients undergoing elective surgery.
Bremerich DH; Lischke V; Asskali F; Förster H; Behne M
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):408-14. PubMed ID: 10984015
[TBL] [Abstract][Full Text] [Related]
11. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats.
Leuschner J; Opitz J; Winkler A; Scharpf R; Bepperling F
Drugs R D; 2003; 4(6):331-8. PubMed ID: 14584961
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyethyl starch in balanced electrolyte solution (Hextend)--pharmacokinetic and pharmacodynamic profiles in healthy volunteers.
Wilkes NJ; Woolf RL; Powanda MC; Gan TJ; Machin SJ; Webb A; Mutch M; Bennett-Guerrero E; Mythen M
Anesth Analg; 2002 Mar; 94(3):538-44; table of contents. PubMed ID: 11867371
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution.
Eisenbach C; Schönfeld AH; Vogt N; Wente MN; Encke J; Stremmel W; Martin E; Pfenninger E; Weigand MA
Intensive Care Med; 2007 Sep; 33(9):1637-44. PubMed ID: 17554522
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the acute hemodynamic effects of hypertonic or colloid infusions immediately after mitral valve repair.
Sirieix D; Hongnat JM; Delayance S; D'Attellis N; Vicaut E; Bérrébi A; Paris M; Fabiani JN; Carpentier A; Baron JF
Crit Care Med; 1999 Oct; 27(10):2159-65. PubMed ID: 10548199
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of hydroxyethyl starch.
Jungheinrich C; Neff TA
Clin Pharmacokinet; 2005; 44(7):681-99. PubMed ID: 15966753
[TBL] [Abstract][Full Text] [Related]
16. HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly.
Lehmann GB; Asskali F; Boll M; Burmeister MA; Marx G; Hilgers R; Förster H
Br J Anaesth; 2007 May; 98(5):635-44. PubMed ID: 17456491
[TBL] [Abstract][Full Text] [Related]
17. An international view of hydroxyethyl starches.
Treib J; Baron JF; Grauer MT; Strauss RG
Intensive Care Med; 1999 Mar; 25(3):258-68. PubMed ID: 10229159
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyethyl starch for fluid resuscitation in critically ill patients.
Bagshaw SM; Chawla LS
Can J Anaesth; 2013 Jul; 60(7):709-13. PubMed ID: 23604905
[TBL] [Abstract][Full Text] [Related]
19. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related.
Sirtl C; Laubenthal H; Zumtobel V; Kraft D; Jurecka W
Br J Anaesth; 1999 Apr; 82(4):510-5. PubMed ID: 10472213
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.
Glover PA; Rudloff E; Kirby R
J Vet Emerg Crit Care (San Antonio); 2014; 24(6):642-61. PubMed ID: 25158892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
